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Introduction
Informed consent has its roots in the 1947 Nuremberg Code 
and the 1964 Declaration of Helsinki and is now a guiding 
principle for conduct in medical research.1,2 Within its ethical 
and legal foundations,3 informed consent has two specific goals 
in clinical research: (i) to respect and promote a participant’s 
autonomy; and (ii) to protect participants from harm.4,5 Ob-
taining written informed consent from participants before en-
rolment in a study is an internationally accepted standard.6–10
Five concepts must be considered in establishing informed 
consent: voluntariness, capacity, disclosure, understanding and 
decision.11,12 Voluntariness means that an individual’s decision 
to participate is made without coercion or persuasion. Capac-
ity relates to an individual’s ability to make decisions that 
stems from his or her ability to understand the information 
provided. Disclosure involves giving research participants all 
relevant information about the research, including its nature, 
purpose, risks and potential benefits as well as the alternatives 
available.13 Understanding implies that research participants 
are able to comprehend the information provided and appreci-
ate its relevance to their personal situations. Decision is that 
made to participate, or not.11,12
The quality of informed consent in clinical research is 
determined by the extent to which participants understand 
the process of informed consent.14 Understanding plays a 
pivotal role in clinical research because it directly affects how 
ethical principles are applied in practice.15–17 Although the 
literature on informed consent began to accumulate in the 
1980s, little is known about how patients’ understanding has 
evolved as no meta-analysis has been previously performed. A 
systematic review considering literature up to 2006 found that 
only around 50% of participants understood all components 
of informed consent in surgical and clinical trials.18 Another 
systemic review, which included data up to 2010, compared 
only the quality of informed consent in developing and devel-
oped countries.19 The objective of this study was, therefore, to 
investigate the quality of informed consent in clinical trials in 
recent decades by performing a systematic review and meta-
analysis of the data available.
Methods
We conducted a literature search of PubMed and Sco-
pus using the following terms: “informed consent[mh] 
AND (comprehension[mh] OR decision making[mh] OR 
knowledge[mh] OR perception[mh] OR communication[mh] 
OR understanding) AND (randomized controlled trials as 
topic[mh] OR clinical trial as topic[mh])”. In addition, in a 
simple search of Scopus, we used: “allintitle: understanding 
OR comprehension OR knowledge OR decision OR perception 
OR communication “informed consent”.” In Google Scholar, 
we used the keywords “informed consent” as the exact phrase 
and “understanding, comprehension, knowledge, decision, 
perception, communication” with the option with at least one 
of the words and selected “where my words occur in the title 
of the article”. The search strategy was developed as previ-
ously described.20 The searches covered all data entered up to 
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October 2013. In addition, we analysed 
the reference lists of relevant articles. 
All studies identified were reviewed in-
dependently for eligibility by two of five 
authors and conflicts were resolved by 
seeking a consensus with other authors.
A study was eligible for inclusion 
if it assessed the participant’s or the 
participant’s guardian’s understanding 
of informed consent1,2 and at least one 
of the following components of the in-
formed consent process:8,21 therapeutic 
misconception (i.e. lack of awareness 
of the uncertainty of success); ability 
to name at least one risk; knowing that 
treatments were being compared; or 
understanding of: (i) the nature of the 
study (i.e. awareness of participating in 
research); (ii) the purpose of the study; 
(iii) the risks and side-effects; (iv) the 
direct benefits; (v) placebo; (vi) ran-
domization; (vii) the voluntary nature 
of participation; (viii) freedom to with-
draw from the study at any time; (ix) the 
availability of alternative treatment if 
withdrawn from a trial; or (x) confiden-
tiality (i.e. personal information will not 
be revealed). There was no restriction 
by language, age (i.e. children or adults) 
or study design. French and Japanese 
articles were translated into English by 
authors with a good command of these 
languages. We excluded articles on 
studies that: (i) compared or evaluated 
methods of informed consent; (ii) used 
an intervention to improve partici-
pants’ knowledge of informed consent; 
(iii) involved animals or included only 
healthy volunteers (e.g. simulated stud-
ies); (iv) involved patients with cognitive 
deficits; (v) were published as posters, in 
conference proceedings or as a thesis; or 
(vi) were not clinical trials. Our study 
protocol was registered with the interna-
tional prospective register of systematic 
reviews (PROSPERO) with the identifier 
CRD42013005526. The study selection 
process, which was carried out in ac-
cordance with MOOSE guidelines for 
meta-analyses and systematic reviews 
of observational studies, is shown in 
Fig. 1.22
Quality of evaluation
The quality of the informed consent 
evaluation was assessed independently 
by two authors using seven metrics: 
(i) the description of participants; 
(ii) whether or not interviewers were 
members of the original trial’s staff; 
(iii) the description of the evalua-
tion method (i.e. by questionnaire or 
interview); (iv) the description of the 
questionnaire; (v) the selection of par-
ticipants (i.e. consecutive participants or 
a random or cross-sectional selection); 
(vi) the description of exclusion criteria; 
and (vii) the timing of the evaluations. 
Quality scores for the studies included 








Data were extracted for each study on: 
(i) the year of publication; (ii) the study 
language and the country where the 
study was conducted; (iii) the phase of 
the study; (iv) the baseline characteris-
tics of the study population, including 
the source of the population, the number 
of participants and their age, sex and 
educational level; (v) the medical spe-
cialty of the clinical research, including 
the seriousness of the disease studied; 
(vi) the method and timing of the 
informed consent evaluation; (vii) the 
type of questions participants had to 
answer; and (viii) the components of 
informed consent assessed, including 
understanding of the nature and pur-
pose of the study, knowing that treat-
ments were being compared, therapeutic 
misconceptions, participants’ ability to 
name risks, awareness of potential risks 
and side-effects and understanding of 
potential benefits, randomization, pla-
cebo, the voluntary nature of participa-
tion, freedom to withdraw at any time, 
confidentiality and the availability of 
alternative treatment.
Statistical analysis and data 
synthesis
If a study investigated more than one 
population, a data set was created for 
each population. The proportion of par-
ticipants who understood the different 
components of informed consent was 
pooled across studies using Compre-
hensive Meta-Analysis software version 
2.0 (Biostat, Englewood, United States 
of America) and was expressed as a per-
centage with 95% confidence intervals 
(CIs). The heterogeneity of study find-
ings was evaluated using the Q statistic 
and the I2 test and was considered sig-
nificant if the P-value was < 0.10. Since 
studies gave heterogeneous results for all 
components, the proportion of partici-
pants who understood each component 
was pooled using a random-effects mod-
el that included weighting for each study. 
In examining the effect of covariates on 
these proportions, we used a subgroup 
or meta-regression analysis when eight 
or more studies assessed a particular co-
variate. Differences between subgroups 
and trends were considered significant 
if the P-value of Cochran’s Q test was 
< 0.05.23 To determine if publication bias 
was present, we used Begg’s funnel plot 
and Egger’s regression test: a P-value 
< 0.10 indicated significant publication 
Fig. 1. Flow diagram for the selection of studies on participants’ understanding of 
informed consent in clinical trials
3511 papers identified in literature search
1022  from PubMed
1713  from Scopus
776 from Google Scholar
78 papers were excluded because:
• the study included no relevant items
• data could not be extracted
• they were reviews                                        
• they were case reports                                
• the study was carried out in healthy 
individuals
• data overlapped data in other papers                
• the study involved patients with 
cognitive deficits
• they were posters, in conference 
proceedings or theses, or
• the study was not a clinical trial
2704 papers had titles and abstracts screened
163 papers underwent full text review
Reference lists analysed
103 papers (135 data sets) included in final analysis
Duplicates removed
18 papers 85 papers
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bias.24 When publication bias was pres-
ent, we used Duvall and Tweedie’s trim-
and-fill method to enhance symmetry 
by adjusting for studies that appeared 
to be missing.25–27 The final proportion 
of participants who understood each 
component was computed after adjust-
ment for missing studies.
Results
The final analysis included 103 studies: 
85 from the database search and 18 from 
reviewing reference lists.28–130 Ultimately 
135 data sets were included because 
some studies evaluated more than one 
population (Appendix A). The sample 
size ranged from 8 to 1789 participants 
and the response rate to interview ques-
tions ranged from 9.3% to 100%. Partici-
pants were adults in 95 data sets, parents 
or guardians in 34, adult and child pa-
tients in three, child patients in two and 
adult patients or parents in one. Overall, 
79% (106) of data sets were conducted 
in middle- or high-income countries – 
as classified by the World Bank131 – and 
67% (90) did not report the phase of 
the clinical trial. The medical specialty 
was cancer in 33% (44) of data sets, 
infectious disease in 14% (19), vaccines 
in 10%, (13) cardiovascular disease in 
7% (9), neurology in 6% (8) and other 
in 31% (42). Moreover, 98% (132) were 
published in English and only 1% each 
in Japanese (1) and French (2). Details 
of the studies and data sets are presented 
in Table 1 (available at: http://www.who.
int/bulletin/volumes/93/3/14-141390).
Understanding of informed 
consent
The number of data sets that covered 
each component of informed consent 
is shown in Appendix B. Understanding 
of freedom to withdraw at any time was 
investigated in the largest number of 
studies (n = 79), whereas understand-
ing of placebo was investigated in the 
smallest number (n = 15). Our analysis 
showed some variation in the propor-
tion of participants who understood 
different components of informed 
consent. The highest proportions were 
75.8% (95% CI: 70.6–80.3) for freedom 
to withdraw from the study at any time, 
74.7% (95% CI: 68.8–79.8) for the na-
ture of study, 74.7% (95% CI: 67.9–80.5) 
for the voluntary nature of participation 
and 74.0% (95% CI: 65.0–81.3) for po-







meta-analysis). Lower proportions 
were 69.6% (95% CI: 63.5–75.1) for 
the purpose of the study, 67.0% (95% 
CI: 57.4–75.4) for potential risks and 
side-effects, 66.2% (95% CI: 55.3–75.7) 
for confidentiality, 64.1% (95% CI: 
53.7–73.4) for the availability of al-
ternative treatment if withdrawn and 
62.9% (95% CI: 45.5–77.5) for knowing 
that treatments were being compared. 
In addition, 62.4% (95% CI: 50.1–73.2) 
had no therapeutic misconceptions. The 
lowest proportions were 54.9% (95% CI: 
43.3–65.0) for naming at least one risk, 
followed by 53.3% (95% CI: 38.4–67.6) 
for understanding of placebo and 52.1% 
(95% CI: 41.3–62.7) for understanding 
of randomization.
Effect of covariates
We performed a meta-regression analysis 
to evaluate the influence of particular 
covariates on the proportion of partici-
pants who understood informed consent 
(Table 2). We found that gender had 
no effect but that, importantly, signifi-
cantly fewer patients from low-income 
countries than from middle- and high 
countries understood randomization, 
the voluntary nature of participation 
and freedom to withdraw at any time. 
In addition, critically ill patients were 
significantly less likely to understand the 
nature or benefits of the study or confi-
dentiality or to be able to name at least 
one risk. However, older participants 
were more likely to understand the nature 
of the study and freedom to withdraw at 
any time. A lower educational level was 
associated with a reduced likelihood of 
understanding the nature of the study, 
placebo, randomization and freedom 
Fig. 2. Participants’ understanding of components of informed consent in clinical trials, 
by meta-analysisa 
Component of informed consent




























Voluntary nature of participation
Purpose of study
Benefits of the study
Freedom to withdraw at any time
No therapeutic misconception
Placebo
Availability of alternative treatment if withdrawn
Ability to name at least one risk
Randomization
Knowing that treatments were being compared
Confidentiality
Proportion of participants (%)
0 20 40 60 80 100
a  The number of studies included in the evaluation of each component is given.
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Table 2. Influencea of covariates on participants’ understanding of informed consent in clinical trials
Component of 
informed consent
Effect of covariate on understanding of component



















Quality of  
evaluationb
Nature of the study None None None None Increased Decreased Decreased None None None
Purpose of the study None None Decreased None None None None None Decreased None
No therapeutic 
misconceptionc
None NDd Decreased None None ND None None None None
Ability to name at 
least one risk
None None None None None Decreased None Decreased Decreased None
Risks and side-effects None None Increased None None None None None None None
Benefits of the study None None None None None Decreased None None None None




None ND ND None None ND None None ND None
Randomization None Decreased ND None None None Decreased None None None
Voluntary nature of 
participation
None Decreased ND None None None None None Decreased None
Freedom to withdraw 
at any time




None None None None None ND None None None None
Confidentiality None None ND ND None Decreased None Decreased ND None
ND: not determined.
a  The influence of the covariate on participants’ understanding of the component of informed consent was evaluated by meta-regression analysis.
b  Continuous variable.
c  No lack of awareness of the uncertainty of success.
d  The effect was not determined because there were fewer than five studies per subgroup or fewer than 10 for the regression analysis.
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to withdraw at any time. Participants 
in phase-I clinical trials were less likely 
than participants in phase-II, -III or 
-IV trials to understand the purpose of 
the study and were more likely to have 
therapeutic misconceptions. Partici-
pants in phase-I trials were also more 
likely to understand potential risks and 
side-effects and freedom to withdraw 
at any time. Participants assessed us-
ing open-ended questions were less 
likely to understand the purpose of the 
study (Fig. 3), the voluntary nature of 
participation or freedom to withdraw 
at any time or to be able to name at 
least one risk. Additionally, the later the 
evaluation of understanding was carried 
out, the less likely the participant was 
to understand confidentiality or to be 
able to name at least one risk. The qual-
ity of the evaluation did not influence 
understanding.
Our data also provided us with 
the opportunity to analyse how study 
participants’ understanding of informed 
consent had changed over 30 years. Sur-
prisingly, there was no significant change 
in understanding of any component 
(Fig. 4, Fig. 5 and Fig. 6). In particular, 
we were interested in the past 20 years, 
after the World Health Organization 
introduced guidelines for good clini-
cal practice in trials.132 After removing 
four early studies, we again found no 
significant change in understanding of 
any component, including the freedom 
to withdraw (Fig. 7). Furthermore, 
there was no significant change in un-
derstanding of any component over the 
past 13 years in all studies combined or 
in subgroups of participants, including 
those assessed using open-ended ques-
tions, those assessed using closed-ended 
questions and those in middle- and 
high-income countries assessed using 
closed-ended questions (Appendices 








Obtaining informed consent from par-
ticipants in clinical research is essen-
tial because it promotes their welfare 
and ensures their rights.9,133 However, 
participants must have a good under-
standing of what informed consent 
entails. Our meta-analysis indicates 
that around 75% of individuals un-
derstood the nature of the study, their 
right to refuse to participate, their right 
to withdraw at any time and the direct 
benefits of participation. This percent-
age is higher than the figure of around 
50% found in a previous systematic 
review18 probably because we included 
only clinical trials, excluded studies 
of patients with cognitive deficits and 
weighted the meta-analysis to account 
for heterogeneous data.
Our data also highlight the diffi-
culty participants had in understand-
ing particular components of informed 
consent, such as randomization and 
the use of placebo. Moreover, although 
Fig. 3. Effect of using an open-ended questiona on participants’ understanding of the 
purpose of a clinical studyb
Study reference Proportion of participants (95% CI)
Closed-ended question  
Minnies 2008 0.81 (0.74–0.86)
Krosin 2006 (rural) 0.20 (0.09–0.38) 
Krosin 2006 (urban) 0.28 (0.20–0.39)
Pace 2005 0.88 (0.81–0.92)
Joubert 2003 0.28 (0.20–0.38)
Lynöe 2004 (hemodialysis) 0.77 (0.63–0.87)
Lynöe 1991 0.86 (0.72–0.94)
Lynöe 2004 (cancer) 0.92 (0.79–0.97)
Lynöe 2001 (male) 0.88 (0.70–0.96)
Lynöe 2001 (female) 0.81 (0.55–0.94)
Franck 2007 0.89 (0.82–0.94)
Gammelgaard 2004 (trial-participants) 0.72 (0.62–0.80)
Gammelgaard 2004 (trial-non-participants) 0.46 (0.35–0.57)
Joffe 2001 0.75 (0.69–0.80)
Bertoli 2007 0.67 (0.58–0.76)
Burgess 2003 (prospective) 0.98 (0.78–1.00)
Burgess 2003 (retorspective) 0.93 (0.80–0.98)
Chaisson 2011 (English) 0.96 (0.95–0.97)
Chaisson 2011 (Setswana) 0.94 (0.92–0.95)
Durand-Zaleski 2008 0.73 (0.67–0.78)
Itoh 1997 0.43 (0.27–0.61)
Nurgat 2005 0.97 (0.84–1.00)
Pooled subgroup 0.78 (0.69–0.85)
  
Open-ended question  
Vallely 2010 0.77 (0.67–0.84)
Knifed 2008 0.98 (0.72–1.00)
Kupst 2003 0.95 (0.72–0.99)
Van Stuijvenberg 1998 0.53 (0.46–0.60)
Harth 1995 0.97 (0.88–0.99)
Howard 1981 0.67 (0.55–0.78)
Griffin 2006 0.65 (0.62–0.67)
Sugarman 2005 0.89 (0.86–0.91)
Pentz 2002 0.33 (0.24–0.43)
Rodenhuis 1984 0.40 (0.16–0.70)
Riecken 1982 0.10 (0.06–0.17)
Ballard 2004 (mothers) 0.90 (0.73–0.97)
Ballard 2004 (fathers) 0.57 (0.36–0.76)
Ballard 2004 (mothers and fathers) 0.75 (0.38–0.94)
Chappuy 2010 0.49 (0.34–0.63)
Chappuy 2013 0.62 (0.44–0.78)
Chappuy 2006 0.75 (0.63–0.84)
Chappuy 2008 0.62 (0.44–0.78)
Cousino 2012 (ethnic majority) 0.65 (0.52–0.76)
Cousino 2012 (ethnic minority) 0.33 (0.11–0.67)
Eiser 2005 0.28 (0.17–0.42)
Kass 2005 0.36 (0.20–0.56)
Manafa 2007 0.47 (0.36–0.57)
Mangset 2008 0.04 (0.00–0.42)
Schutta 2000 0.94 (0.50–1.00)
Pooled subgroup 0.62 (0.50–0.72)
Pooled overall 0.71 (0.53–0.84)
0.00 0.50 1.00
CI: confidence interval.
a  Participants’ understanding of components of informed consent was assessed using open-ended or 
closed-ended questions.
b  The pooled proportion of participants who understood the purpose of the study was calculated using 
random-effects models for those assessed using both open-ended and closed-ended questions.
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participants were aware of potential 
risks and side-effects, they were less 
likely to be able to name at least one 
risk and, although they understood 
the benefits of participating in a study, 
they were less aware of the uncertainty 
of these benefits (i.e. had therapeutic 
misconceptions). These findings were 
also noted in previous studies.18,19,134–137 
They are, perhaps, not surprising since 
a participant’s understanding depends, 
to a certain degree, on their literacy as 
well as on the duration of the informed 
consent process and the explanatory 
skills of the researchers.138–140
In addition, the meta-regression 
was able to identify differences in under-
standing of informed consent between 
population groups. Older participants 
more often than younger participants 
understood the nature of the study 
and freedom to withdraw at any time. 
The reason for this difference requires 
further study. As noted in a previous 
systematic review,19 participants from 
developing countries were less likely 
than others to understand the voluntary 
nature of participation and freedom 
to withdraw at any time. It is possible 
that patients in these countries dare 
not refuse to join or dare not withdraw 
from a study because they fear their doc-
tor’s disapproval.141 Participants from 
developing countries and those with a 
low level of literacy were less likely to 
understand randomization.
Phase-I clinical trials are usu-
ally conducted in small numbers of 
participants to test a drug’s safety 
and dose range. Consequently, it was 
expected that participants in phase-I 
trials would be less likely than those in 
more advanced trials to understand the 
purpose of the study or that the benefits 
were uncertain. In contrast, participants 
in phase-I trials were more likely to be 
aware of potential risks and of their 
freedom to withdraw at any time.
Compared with the use of open-
ended questions to evaluate participants’ 
understanding, the use of closed-ended 
questions was associated with higher rates 
of understanding of the purpose of the 
study, the voluntary nature of participation 
and freedom to withdraw and with a great-
er likelihood of being able to name at least 
one risk. However, the use of closed-ended 
questions could have led to understanding 
being overestimated because respondents 
had to choose from a limited number of 
possible answers and did not have to think 
clearly about the issues.142 Consequently, 
the use of open-ended questions may have 
reflected better the true extent of under-
standing since respondents had to put their 
understanding into words.143
Finally, an unexpected finding of 
our analysis was that understanding 
of the potential risks and side-effects 
of trials, of placebo and of freedom 
to withdraw had not changed over 
30 years. This is despite considerable 
progress in medical research methods 
over this time144 and many attempts 
made to improve the quality of informed 
consent.145 There are four possible expla-
nations: (i) the maximum proportion 
of participants who understand these 
concepts has been reached; (ii) the 
increasing complexity of clinical trials 
has made the informed consent process 
longer and more difficult to understand; 
(iii) not enough effort has been put into 
enhancing the quality of the informed 
consent process; and (iv) our analysis 
did not have the statistical power to 
detect a significant increase in under-
standing. In fact, the best way to improve 
understanding of informed consent is 
still debated. A recent meta-analysis 
of interventions for improving under-
standing found that enhanced consent 
Fig. 4. Participants’ understanding of the potential risks and side-effects of 















































Derived by meta-regression analysis
Year
1975 1983 1991 1999 2007 2015
a  The logit event rate is the natural logarithm of the event rate divided by (1 – event rate), where the 
event rate is the proportion of study participants who understood the potential risks and side-effects of 
participating in a clinical study.















































Derived by meta-regression analysis
Year
1975 1983 1991 1999 2007 2015
a  The logit event rate is the natural logarithm of the event rate divided by (1 – event rate), where the 
event rate is the proportion of study participants who understood placebo.
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forms and extended discussions led to 
significant increases in understanding 
whereas multimedia approaches did 
not.146 In other words, simple measures 
such as well formatted, easily readable 
consent forms and intensive discussions 
with participants may be more effective 
than more complex measures.140,146–148
Although an understanding of all 
the components of informed consent we 
investigated is required for patients to 
make a decision on study participation, 
some components were assessed more 
often than others. We found a good 
correlation between the likelihood that a 
participant would understand a specific 
component of informed consent and 
the number of studies that investigated 
understanding of that component (Ap-
pendix G). This suggests either that it 
was simpler to evaluate understanding 
of some components or that some com-
ponents were more important.
One limitation of our study is that 
we were not able to analyse the effect 
on understanding of informed consent 
of the presence of a nurse during the 
informed consent process, of the dura-
tion of the process or of participants 
choosing not to take part in a clinical 
trial because only a small number of 
studies investigated these factors. More-
over, only 79 of the 135 data sets gave 
information on whether the interview-
ers were investigators in the original 
clinical trial. Hence, we were not able 
to analyse the effect of this factor on 
the results. Another limitation is that 
we included studies of children because 
they have the right to decide whether to 
participate.149,150 However, the number 
of studies involving children was small 
and our sensitivity analysis showed that 
removing these studies did not influence 
the pooled results. Although we found a 
high level of heterogeneity across studies 
for understanding of all components of 
informed consent and although Cox et 
al. suggest that, in these circumstances, 
individual studies should be described 
rather than combined in a meta-anal-
ysis,151 we, like other groups, chose to 
perform a meta-analysis with a regres-
sion analysis and subgroup analysis to 
gain a better insight into how covariates 
affect understanding.152–154
In conclusion, we found that most 
participants in clinical trials understood 
fundamental components of informed 
consent such as the nature and benefits 
of the study, freedom to withdraw at 
any time and the voluntary nature of 
participation. Understanding of other 
components, such as randomization and 
placebo, was less satisfactory and has not 
improved over 30 years. Our findings 
suggest that investigators could make 
a greater effort to help research partici-
pants achieve a complete understanding 
of informed consent. This would ensure 
that participants’ decision-making is 
meaningful and that their interests are 
protected. ■
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Derived by meta-regression analysis
Year
1975 1983 1991 1999 2007 2015
a  The logit event rate is the natural logarithm of the event rate divided by (1 – event rate), where the 
event rate is the proportion of study participants who understood they were free to withdraw from the 
study at any time.
Fig. 7. Participants’ understanding of their freedom to withdraw from a study at any 















































Derived by meta-regression analysis
Year
1990 1995 2000 2005 2010 2015
a  The logit event rate is the natural logarithm of the event rate divided by (1 – event rate), where the 
event rate is the proportion of study participants who understood they were free to withdraw from the 
study at any time.
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ملخص
فهم املشاركني للموافقة املستنرية يف التجارب الرسيرية عىل مدى ثالثة عقود: استعراض منهجي وحتليل تاٍل
الغرض تقدير نسبة املشاركني يف التجارب الرسيرية الذين يفهمون 
العنارص املختلفة للموافقة املستنرية.
استعراض  طريق  عن  الصلة  ذات  الدراسات  حتديد  تم  الطريقة 
 Googleو  Scopusو  PubMed بيانات  لقواعد  منهجي 
اخلاصة  املراجع  لقوائم  يدوي  استعراض  طريق  وعن   Scholar
باملنشورات حتى ترشين األول/أكتوبر 2013. وتم إجراء حتليل 
العشوائية لوضع  التأثريات  الدراسة باستخدام نموذج  لنتائج  تال 
التغايرية يف احلسبان.
النتائج اشتمل التحليل عىل 103 دراسة تقوم بتقييم 135 جمموعة 
فهموا  الذين  للمشاركني  املجمعة  النسبة  وكانت  املشاركني.  من 
يف  االنسحاب  حلرية  بالنسبة   % 75.8 املستنرية  املوافقة  عنارص 
بالنسبة  و74.7 %  الدراسة  لطبيعة  بالنسبة  و74.7 %  وقت  أي 
املحتملة  للفوائد  بالنسبة  و74.0 %  الطوعية  املشاركة  لطبيعة 
للمخاطر  بالنسبة  و67.0 %  الدراسة  لغرض  بالنسبة  و69.6 % 
املعلومات  لرسية  بالنسبة  و66.2 %  املحتملة  اجلانبية  واآلثار 
من  االنسحاب  يف حالة  البديل  العالج  بالنسبة إلتاحة  و64.1 % 
بني  مقارنات  إجراء  ملعرفة  بالنسبة  و62.9 %  الرسيرية  التجربة 
بالنسبة  و52.1 %  الومهي  للدواء  بالنسبة  و53.3 %  العالجات 
 ،% 62.4 املشاركني،  معظم  لدى  يكن  ومل  العشوائي.  للتوزيع 
54.9 % حتديد خطر واحد عىل  مفاهيم عالجية خاطئة واستطاع 
األقل. وحددت حتليالت الفئات الفرعية وحتليالت االرتداد التايل 
التعليمي واالعتالالت  السن واملستوى  مثل  املصاحبة،  املتغريات 
أثرت بشكل كبري عىل  والتي  الدراسة وموقعها،  احلرجة ومرحلة 
الفهم وأشارت إىل أن نسبة املشاركني الذين فهموا املوافقة املستنرية 
مل تشهد زيادة عىل مدار 30 سنة.
الذين  الرسيرية  التجارب  يف  املشاركني  نسبة  تراوحت  االستنتاج 
إىل   % 52.1 من  املستنرية  للموافقة  املختلفة  العنارص  فهموا 






方法 系统回顾 PubMed、Scopus 和 Google Scholar 来识
别相关研究。使用随机影响模型执行研究结果荟萃分
析，以便将异质性考虑在内。













52.1% 到 75.8% 不等。研究者可以做更多的工作来帮助
参与者完全理解各个组成部分。
Résumé
Compréhension du consentement éclairé par les participants à des essais cliniques sur trois décennies: revue systématique et 
méta-analyse
Objectif Estimer la proportion des participants à des essais cliniques 
qui comprennent les différents composants du consentement éclairé.
Méthodes Les études pertinentes ont été identifiées par une revue 
systématique de PubMed, Scopus et Google Scholar et par l’examen 
manuel des listes des références des publications allant jusqu’à 
octobre 2013. Une méta-analyse des résultats de l’étude a été réalisée à 
l’aide du modèle à effets aléatoires pour tenir compte de l’hétérogénéité.
Résultats L’analyse a inclus 103 études évaluant 135 cohortes de 
participants. La proportion regroupée des participants qui ont compris 
les composants du consentement éclairé était de 75,8% pour la liberté 
de se retirer à tout moment, de 74,7% pour la nature de l’étude, de 74,7% 
pour la nature volontaire de la participation, de 74,0% pour les bénéfices 
potentiels, de 69,6% pour l’objectif de l’étude, de 67,0% pour les risques 
et effets indésirables potentiels, de 66,2% pour la confidentialité, de 
64,1% pour la disponibilité d’un traitement alternatif en cas de retrait 
de l’étude, de 62,9% pour la connaissance des traitements évalués, de 
53,3% pour le placebo et de 52,1% pour la randomisation. La plupart 
des participants (62,4%) n’avaient pas d’idées fausses sur le traitement, 
et 54,9% d’entre eux pouvaient citer au moins un risque. Les analyses 
de sous-groupe et de métarégression ont identifié des covariables, 
telles que l’âge, le niveau d’éducation, la maladie grave, la phase et 
le site de l’étude, qui affectaient significativement la compréhension 
et indiquaient que la proportion des participants ayant compris le 
consentement éclairé n’avait pas augmenté sur une période de 30 ans.
Conclusion La proportion des participants à des essais cliniques, qui 
ont compris les différents composants du consentement éclairé, variait 
de 52,1% à 75,8%. Les investigateurs pourraient en faire davantage pour 
aider les participants à parvenir à la compréhension complète. 
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Резюме
Понимание участниками клинических исследований информированного согласия за три десятилетия: 
систематический обзор и мета-анализ
Цель Определить долю участников клинических исследований, 
которые понимают различные детали информированного 
согласия.
Методы Соответствующие исследования были выявлены 
посредством систематического обзора PubMed, Scopus и Google 
Scholar, а также путем просмотра вручную библиографических 
списков публикаций, изданных до октября 2013 г. Мета-анализ 
результатов исследований проводился с помощью модели со 
случайными эффектами для учета разнородности.
Результаты Анализ включал 103 исследования с оценкой 
135 групп участников. Общие доли участников, которые 
понимали следующие компоненты информированного согласия, 
составляли: 75,8% — о праве прекратить участие в исследовании 
в любое время, 74,7% — о природе исследования, 74,7% — о 
добровольном участии, 74,0% — о потенциальной пользе, 
69,6 — о целях исследования, 67,0% — о потенциальных рисках 
и нежелательных явлениях, 66,2% — о конфиденциальности, 
64,1% — о наличии альтернативного лечения при выходе 
из исследования, 62,9% — о знании сравнения терапий, 
53,3% — о плацебо и 52,1% — о рандомизации. Большинство 
участников, а именно 62,4%, имели правильное представление 
о терапии и 54,9% могли назвать по меньшей мере один риск. 
С помощью анализа данных в подгруппах и мета-регрессионного 
анализа были определены независимые переменные, такие 
как возраст, уровень образования, критическое заболевание, 
место проведения и фаза исследования, которые оказывали 
значительное влияние на понимание и указывали на то, что 
доля участников, понимающих информированное согласие, не 
увеличилась за 30 лет.
Вывод Доля участников клинических исследований, которые 
понимали различные компоненты информированного 
согласия, варьировалась в диапазоне от 52,1% до 75,8%. 
Исследователи могли бы предпринять дополнительные меры, 
чтобы участники исследований в более полной мере поняли 
суть информированного согласия.
Resumen
La comprensión del consentimiento informado por parte de los participantes de ensayos clínicos a lo largo de tres décadas: 
revisión sistemática y metaanálisis
Objetivo Estimar la proporción de participantes de ensayos clínicos que 
comprende los distintos componentes del consentimiento informado.
Métodos Se identificaron los estudios pertinentes mediante una 
revisión sistemática de PubMed, Scopus y Google Scholar y el examen 
manual de listas de referencia a fin de hallar publicaciones anteriores a 
octubre de 2013. Se realizó un metanálisis de los resultados del estudio 
mediante un modelo de efectos aleatorios para tener en cuenta la 
heterogeneidad.
Resultados El análisis incluyó 103 estudios que evaluaron 135 
cohortes de participantes. La proporción combinada de participantes 
que entendía los componentes del consentimiento informado fue 
del 75,8 % para la libertad de retirarse en cualquier momento, 74,7 % 
para la naturaleza del estudio, 74,7 % para el carácter voluntario de la 
participación, 74,0 % para los beneficios potenciales, 69,6 % para el 
propósito del estudio, 67,0 % para los riesgos y efectos secundarios 
potenciales, 66,2 % para la confidencialidad, 64,1 % para la disponibilidad 
de tratamiento alternativo si el paciente se retira, 62,9 % para saber que 
se comparaban tratamientos, 53,3 % para el placebo y 52,1 % para la 
aleatorización. La mayoría de los participantes, el 62,4 %, no tenía una 
idea equivocada sobre la terapia y el 54,9 % no fue capaz de nombrar 
al menos un riesgo. Los análisis de subgrupos y la metarregresión 
identificaron covariables, como edad, nivel educativo, enfermedad 
crítica, fase de estudio y ubicación, que influían considerablemente 
en la comprensión y señalaron que la proporción de participantes que 
entendía el consentimiento informado no había aumentado en 30 años.
Conclusión La proporción de participantes de ensayos clínicos que 
entendía los diferentes componentes del consentimiento informado 
varió del 52,1 % al 75,8 %. Los investigadores podrían realizar esfuerzos 
mayores para ayudar a los pacientes a lograr una comprensión total.
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Table 1. Studies and data sets in the meta-analysis of participants’ understanding of informed consent in clinical trials, 1980–2013
Study Year Country  
(data set, if applicable)






Evaluation of understanding of informed consent
Type No. Age,a years Method Timing
Ellis28 2010 USA Adult patients 171 30 (18–50) Malaria vaccine I No Questionnaire After ICP
Ellis28 2010 Mali Adult patients 89 27 (18–50) Malaria vaccine I No Questionnaire After ICP
Ellis28 2010 Mali Parents or 
guardians
700 ND Malaria vaccine I No Questionnaire After ICP
Vallely29 2010 United Republic of 
Tanzania
Adult patients 99 ND Infectious disease III No Interviews 4 weeks after ICP
Hill30 2008 Ghana Adult and 
child patients





ND No Semi-structured 
interviews
After ICP
Minnies31 2008 South Africa Parents or 
guardians
192 26 (16–44) Infectious disease ND No Questionnaire with 
staff assistance
Within 1 hour of ICP




At third follow-up visit
Krosin33 2006 Mali (rural population) Adult patients 78 ND Malaria vaccine ND No Questionnaire Within 48 hours of consent
Krosin33 2006 Mali (urban population) Adult patients 85 ND Malaria vaccine ND No Questionnaire Within 48 hours of consent
Moodley34 2005 South Africa Adult patients 334 68 (60–80) Influenza vaccine ND No Interviews 4–12 months after the trial
Pace35 2005 Thailand Adult patients 141 > 18 Infectious disease III No Interviews Immediately after ICP
Pace36 2005 Uganda Parents or 
guardians
347 ND Infectious disease ND No Interviews Immediately after ICP
Ekouevi37 2004 Côte d’Ivoire Adult patients 55 26 Infectious disease ND No Interviews ND
Joubert38 2003 South Africa Adult patients 92 27 Vitamin A 
supplementation
ND No Interviews Median of 14 months after ICP
Lynöe39 2001 Bangladesh Adult patients 105 ND Iron supplementation ND No Structured 
questionnaire
After ICP
Lynöe40 2004 Sweden Adult patients 44 67.8 (39–82) Lipid-lowering 
treatment
ND No Questionnaire 1 week after ICP
Lynöe41 1991 Sweden Adult and 
child patients
43 23 (16–35) Gynaecology ND No Questionnaire by 
mail
18 months after the trial
Lynöe42 2004 Sweden ND 40 ND Oncology ND No Questionnaire ND
Lynöe43 2001 Sweden Adult patients 26 33 (21–50) Auricular acupuncture ND No Questionnaire 4 weeks after ICP
Lynöe43 2001 Sweden Adult patients 16 38 (26–45) Auricular acupuncture ND No Questionnaire 4 weeks after ICP




73 ND Haemophilus influenza 
type B vaccine
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Study Year Country  
(data set, if applicable)






Evaluation of understanding of informed consent
Type No. Age,a years Method Timing




64 ND Haemophilus influenza 
type B vaccine
ND No Interviews Within 1 week of ICP
Pitisuttithum45 1997 Thailand Adult patients 33 55.3 (43–69) HIV vaccine I, II No Questionnaire Prior to ICP
Bergenmar46 2008 Sweden Adult patients 282 60 (32–82) Oncology II, III No Questionnaire 75% within 3 days of ICP, 99% 
within 2 weeks
Knifed47 2008 Canada Adult patients 21 52 (26–65) Neuro-oncology I, II, III No Face-to-face 
interviews
Within 1 month of ICP
Agrawal48 2006 USA Adult patients 163 57.7 (IQR: 
48–68)
Oncology I No Structured 
interview
Immediately after ICP
Franck49 2007 United Kingdom Parents or 
guardians
109 ND 25 paediatric trials ND Yes Questionnaire Immediately after ICP
Gammelgaard50 2004 Denmark (patients 
participating in trial)
Adult patients 103 60 Acute myocardial 
infarction
ND Yes Questionnaire ND
Gammelgaard50 2004 Denmark (patients 
declining participation)
Adult patients 78 61 Acute myocardial 
infarction
ND Yes Questionnaire ND
Kodish51 2004 USA (participants with 
nurse present at ICP)
Parents or 
guardians
65 35 (18–51) Paediatric oncology ND No Interview Within 48 hours of ICP
Kodish51 2004 USA (participants with 
nurse not present at ICP)
Parents or 
guardians
72 35 (18–51) Paediatric oncology ND No Interview Within 48 hours of ICP
Criscione52 2003 USA Adult patients 30 44.9 ± 9.8 Rheumatology ND No Questionnaire 7–28 days after ICP
Kupst53 2003 USA Parents or 
guardians
20 ND Paediatric oncology ND No Structured 
interview
1 month after ICP
Pope54 2003 Canada Adult patients 190 63 (22–84) Cardiology, 
ophthalmology and 
rheumatology
III No Questionnaire 2 months to 5 years after ICP
Schats55 2003 Netherlands (patient 
consented, patients’ 
understanding of ICP 
assessed)
Adult patients 37 ND Neurology ND Yes Structured 
interview
7–31 months after ICP
Schats55 2003 Netherlands (patient 
consented, relatives’ 
understanding of ICP 
assessed)
Adult patients 30 ND Neurology ND Yes Structured 
interview
7–31 months after ICP
Schats55 2003 Netherlands (relative 
consented, patients’ 
understanding of ICP 
assessed)
Adult patients 17 ND Neurology ND Yes Structured 
interview
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(data set, if applicable)






Evaluation of understanding of informed consent
Type No. Age,a years Method Timing
Schats55 2003 Netherlands (relative 
consented, relatives’ 
understanding of ICP 
assessed)
Adult patients 17 ND Neurology ND Yes Structured 
interview
7–31 months after ICP
Simon56 2003 USA (ethnic majority) Parents or 
guardians
60 36 (19–51) Paediatric oncology III No Interview 48 hours after ICP





21 34 (21–46) Paediatric oncology III No Interview 48 hours after ICP




27 33 (18–45) Paediatric oncology III No Interview 48 hours after ICP
Joffe57 2001 USA Adult patients 207 55 (57% were 
aged 45–64)
Oncology I, II, III No Questionnaire by 
mail
3–14 days after ICP








Hietanen60 2000 Finland Adult patients 261 65 (48–87) Oncology ND No Questionnaire by 
mail
5–17 months after ICP
Montgomery61 1998 United Kingdom Adult patients 158 ND Anaesthesia ND ND Questionnaire by 
mail
6–24 months after ICP
van Stuijvenberg62 1998 Netherlands Parents or 
guardians
181 34 Paediatrics ND No Questionnaire 1–3 years after ICP
Harrison63 1995 USA (injection-drug 
users)
Adult patients 71 37 (18–56) HIV vaccine II No Questionnaire Before ICP signature
Harrison63 1995 USA (injection-drug 
users and other high-risk 
individuals)
Adult patients 71 37 (18–56) HIV vaccine II No Questionnaire Before ICP signature
Harth64 1995 Australia Parents or 
guardians
62 31 Asthma ND No Interview by 
telephone
6–9 months after entering 
trial
Estey65 1994 Canada Adult patients 29 58 (43–70) Drug trial ND No Interview 1–6 weeks after ICP
Howard66 1981 USA Adult patients 64 55 (30–69) Acute myocardial 
infarction
ND Yes Interview 2 weeks to 15 months after 
ICP
Griffin67 2006 USA Adult patients 1789 65 (53% were 
aged 60–69)
Cholesterol treatment ND No Interview 5.1 years after trial
Guarino68 2006 USA Adult patients 1086 40.7 (27–72) Gulf War veterans’ 
illnesses
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Evaluation of understanding of informed consent
Type No. Age,a years Method Timing
Barrett69 2005 USA Adult patients 8 11.9 (39–76) Oncology II, III No Questionnaire ND
Sugarman70 2005 USA Adult patients 627 67 ± 7.2 Several trials on 
different diseases
ND No Interview by 
telephone
Right after ICP
Simon71 2004 USA Adult patients 79 51.9 ± 11.2 Oncology III No Semi-structured 
interview
ND
Simon71 2004 USA Adult patients 140 35.4 ± 7.6 Oncology III No Semi-structured 
interview
ND
Pentz72 2002 USA Adult patients 100 56 (25–79) Oncology I No Structured 
interview in person 
or by phone or mail
ND
Cohen73 2001 USA Adult patients 46 54.9 ± 8.9 Oncology I No Questionnaire Before treatment
Fortney74 1999 USA Adult patients 15 ND Gynaecology ND No Structured 
interview
9–39 days after ICP
Fortney74 1999 Africa Adult patients 17 ND Gynaecology ND No Structured 
interview
26–250 days after ICP
Fortney74 1999 Latin America group I Adult patients 19 ND Gynaecology ND No Structured 
interview
26–250 days after ICP
Fortney74 1999 Latin America group II Adult patients 19 ND Gynaecology ND No Structured 
interview
26–250 days after ICP
Hutchison75 1998 United Kingdom Adult patients 28 55.4 ± 8.8 Oncology I No Structured 
interview
2–4 weeks after ICP
Négrier76 1995 France Adult patients 24 56 Oncology II No Written 
questionnaire
Immediately after ICP
Tankanow77 1992 USA Adult patients 98 44 (18–76) Drug trials ND ND Interview based on 
a questionnaire
72 hours after ICP
Rodenhuis78 1984 Netherlands Adult patients 10 56 (20–72) Oncology I No Structured 
interview
1–6 months after ICP
Penman79 1984 USA Adult patients 144 55 (18–65) Oncology II, III No Structured 
interview
1–3 weeks after ICP
Goodman80 1984 United Kingdom (first 
study)
Adult patients 14 66 (50–81) Anaesthesia ND Yes Questionnaire Postoperative phase of the 
study
Goodman80 1984 United Kingdom (second 
study)
Adult patients 18 ND Anaesthesia ND Yes Questionnaire Before discharge from 
hospital
Riecken81 1982 USA Adult patients 156 ND 50 clinical trials ND ND Interview < 10 weeks after ICP
Bergler82 1980 USA Adult patients 39 55 Anti-hypertensive 
treatment
ND No Structured 
interview
Immediately after ICP
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Evaluation of understanding of informed consent
Type No. Age,a years Method Timing
PENTA84 1999 Several countries Parents or 
guardians
84 ND Drug trial ND No Questionnaire Before unblinding the 
individual child’s therapy
Ballard85 2004 USA (mothers) Parents or 
guardians
35 26.3 (16–43) Paediatrics ND No Questionnaire 3–28 months after ICP
Ballard85 2004 USA (fathers) Parents or 
guardians
21 26.3 (16–43) Paediatrics ND No Questionnaire 3–28 months after ICP




8 26.3 (16–43) Paediatrics ND No Questionnaire 3–28 months after ICP
Bertoli86 2007 Argentina Adult patients 105 56.3 ± 11.8 Rheumatology III, IV No Questionnaire ND




29 30 (21–41) for 
mothers and 
33.4 for fathers
Neonatology ND Yes Questionnaire Prospective study




44 29.5 (14–40) 
for mothers 
and 33.4 for 
fathers
Neonatology ND Yes Questionnaire > 1 year after ICP
Chaisson88 2011 Botswana (English 
speakers)
Adult patients 969 33 Infectious disease ND No Questionnaire Within 30 days of ICP
Chaisson88 2011 Botswana (Setswana 
speakers)
Adult patients 969 33 Infectious disease ND No Questionnaire Within 30 days of ICP
Chappuy89 2010 France Parents or 
guardians
43 ND Paediatric oncology III No Semi-structured 
interview
After ICP
Chappuy90 2013 France Parents or 
guardians
40 ND Oncology III No Semi-structured 
interview
After study inclusion
Chappuy91 2006 France Parents or 
guardians
68 ND HIV infection or 
oncology




21 days to 2 years after ICP
Chappuy92 2008 France Child patients 29 13.6 ± 2.8 HIV infection or 
oncology





Chenaud93 2006 Switzerland Adult patients 44 54 ± 22 Surgical intensive care 
unit
ND Yes Interview Mean of 10 days (standard 
deviation: 2) after ICP





Constantinou95 2012 Australia (patients 
participating in trial)
Adult patients 20 72.2 ± 10.3 Ophthalmology ND No Interview ND
Constantinou95 2012 Australia (patients 
declining participation)
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Evaluation of understanding of informed consent
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Cousino96 2012 USA (ethnic majority) Parents or 
guardians
60 42 (23–66) Paediatric oncology I No Interview ND
Cousino96 2012 USA (ethnic minority) Parents or 
guardians
60 42 (23–66) Paediatric oncology I No Interview ND
Durand-Zaleski97 2008 France Adult patients 
and parents 
or guardians






ND ND No Structured 
interview
ND
Eiser98 2005 United Kingdom Parents or 
guardians
50 ND Oncology ND No Semi-structured 
interview
3–5 months after diagnosis
Featherstone99 1998 United Kingdom Adult patients 20 ND Urinary retention 
treatment
ND No Semi-structured 
interview
Seven patients within 
3 months and five within 
5 months of randomization; 
eight patients after receiving 
treatment
Hazen100 2007 USA (ethnic majority) Parents or 
guardians
79 ND Paediatric oncology ND No Interview Within 48 hours of ICP
Hazen100 2007 USA (ethnic minority) Parents or 
guardians
61 ND Paediatric oncology ND No Interview Within 48 hours of ICP




Within 3 months of ICP




Within 3 months of ICP
Hofmeijer102 2007 Netherlands (extremely 
urgent treatment)
Adult patients 28 48 ± 8 Neurology ND Yes Interview Median of 13 days (range: 
10–16) after ICP
Hofmeijer102 2007 Netherlands (less urgent 
treatment)
Adult patients 30 69 ± 13 Neurology ND Yes Interview Median of 13 days (range: 
10–16) after ICP
Itoh103 1997 Japan Adult patients 32 58 (30–68) Oncology I No Questionnaire After ICP and before drug 
treatment
Jenkins104 2000 United Kingdom 
(patients participating 
in trial)
Adult patients 147 55 (all > 25) Oncology ND No Postal 
questionnaire
ND
Jenkins104 2000 United Kingdom 
(patients declining 
participation in trial)
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Evaluation of understanding of informed consent
Type No. Age,a years Method Timing
Kass105 2005 Two African and one 
Caribbean country
Adult patients 26 Two thirds 
were 20–30 
and one third 
were 31–40
Infectious disease ND No Semi-structured 
interview
ND
Kenyon106 2006 United Kingdom Adult patients 20 ND Gynaecology ND Yes Interview ND
Kiguba107 2012 Uganda Adult patients 235 38.2 ± 7.5 Infectious disease ND No Semi-structured 
interview
After initial or repeat ICP
Lidz108 2004 USA Adult patients 155 55 (all > 18) 40 trials on several 
diseases





Leroy109 2011 France Adult patients 75 54.7 (28–82) Oncology II, III No Self-assessment 
questionnaire
ND
Levi110 2000 USA Parents or 
guardians
22 ND Paediatric oncology ND No Semi-structured 
interview
ND
Manafa111 2007 Nigeria Adult patients 88 39.2 (26–62) Infectious disease ND No Questionnaire 2 months after enrolment 
in trial
McNally112 2001 United Kingdom Parents or 
guardians
29 32 Infectious disease ND No Questionnaire ND
Mangset113 2008 Norway Adult patients 11 69.9 ± 8.1 Neurology III Yes Semi-structured 
interview
ND




6 months to 4 years after 
completion of trial
Miller115 2013 USA Adult and 
child patients
20 17.8 ± 2.4 Paediatric oncology I No Structured 
interview
Immediately after ICP
Mills116 2003 United Kingdom Adult patients 21 60 (50–69) Oncology ND No Interview Approximately10 days after 
ICP
Nurgat117 2005 United Kingdom Adult patients 38 60 (37–79) Oncology I, II No Questionnaire by 
mail
Before or during the first 
treatment cycle
Ockene118 1991 USA Adult patients 28 ND Cardiology I Yes Interview based on 
a questionnaire
After ICP




767 ND Paediatric oncology ND No Questionnaire by 
mail
ND




40 ND Paediatric oncology ND No Questionnaire by 
mail
ND
Queiroz da Fonseca120 1999 Brazil Adult patients 66 18–49 HIV vaccine ND No Semi-structured 
interview
ND
Russell121 2005 Australia (Aborigines) Adult patients 20 95% were 
> 16
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Evaluation of understanding of informed consent
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Russell121 2005 Australia (non-
Aborigines)
Adult patients 20 100% were 
> 16
Pneumococcal vaccine ND No Semi-structured 
interview
Immediately after ICP
Schaeffer122 1996 USA (phase1) Adult patients 9 53 ± 14.7 Oncology I No Questionnaire 24 hours after study inclusion
Schaeffer122 1996 USA (phase 2) Adult patients 36 56 ± 8.9 Oncology I No Questionnaire 24 hours after study inclusion
Schaeffer122 1996 USA (phase 3) Adult patients 28 33 ± 6.6 Infectious disease I No Questionnaire 24 hours after study inclusion
Coulibaly-Traore123 2003 France Adult patients 57 25 (18–42) HIV vaccine ND No Interview 90–180 days after ICP
Ducrocq124 2000 France Adult patients 72 62 (29–85) Neurology ND No Interview 6–24 hours after study 
inclusion
Schutta125 2000 USA Adult patients 8 57 (42–72) Oncology I No Interview Immediately after ICP
Snowdon126 1997 United Kingdom Parents or 
guardians
71 30.5 (22–44) Neonatology ND Yes Semi-structured 
interview
Different times after 
recruitment to the trial
Stenson127 2004 United Kingdom Parents or 
guardians
99 ND Neonatology ND Yes Questionnaire 18 months after the study 
finished





Yoong129 2011 Australia Adult patients 102 ND Oncology I, II, III No Questionnaire ND
Verheggen130 1996 Netherlands Adult patients 198 ND 26 trials ND No Questionnaire 4 weeks after ICP
HIV: human immunodeficiency virus; ICP: informed consent process; IQR: interquartile range; ND: not determined.
a  Ages are given as a mean alone, a mean ± standard deviation, a range or a median (range), unless otherwise stated.
(. . .continued)
